ENHO encodes adropin, a secreted peptide hormone that regulates energy homeostasis, glucose metabolism, and lipid homeostasis 1. The protein functions as an anti-fibrotic factor, with reduced ENHO/adropin expression observed in systemic sclerosis (SSc) patients, where TGFβ downregulates ENHO through JNK-dependent mechanisms 2. Adropin exerts its anti-fibrotic effects by binding to GPR19 receptor and deactivating GLI1-dependent profibrotic transcriptional networks 2. In vascular contexts, adropin inhibits atherosclerosis progression by preventing endothelial-to-mesenchymal transition through suppression of TGF-β/Smad2/3 signaling 3. The gene shows tissue-specific expression patterns reflecting circadian control, with strong correlations to lipoprotein metabolism in liver and mitochondrial oxidative processes across tissues 4. ENHO expression is associated with immune regulation, particularly macrophage polarization, where adropin promotes M1-to-M2 macrophage repolarization through PPARγ-mediated lipid metabolism regulation 5. Genetic variants in ENHO are associated with dyslipidemia patterns and cardiovascular outcomes in hemodialysis patients 1. The protein serves as a potential biomarker for early SSc diagnosis when combined with NOX4 6.